Trial Profile
Breaking Innate PD-1 Inhibitor (PD1i) Resistance Using Epigenetic Modifiers; Antitumor Efficacy and Correlative Analyses of Entinostat Plus Pembrolizumab in Non-Inflamed Metastatic Melanoma (MM)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Entinostat (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 14 Sep 2023 Status changed from active, no longer recruiting to completed.
- 10 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 08 May 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2022.